Trial reportDigestive diseases and sciences2007
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon.
Trial report in Digestive diseases and sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug.Inflammopharmacology · 2021Pooled it
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines.Techniques in coloproctology · 2015Guideline
- Systematic review of medical therapy to prevent recurrent diverticulitis.International journal of colorectal disease · 2012Pooled it
- Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.Alimentary pharmacology & therapeutics · 2017Trial
- Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.Drug design, development and therapy · 2014Trial
- Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.International journal of colorectal disease · 2013Trial
- Trial
- Treatment of diverticular disease: an update on latest evidence and clinical implications.Drugs in context · 2018Review
- Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis.World journal of gastroenterology · 2015Article
- Italian consensus conference for colonic diverticulosis and diverticular disease.United European gastroenterology journal · 2014Article
- New strategies for the management of diverticular disease: insights for the clinician.Therapeutic advances in gastroenterology · 2013Article
- Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.Digestive diseases and sciences · 2011Review
- Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.Therapeutic advances in gastroenterology · 2011Article
- Absence of mucosal inflammation in uncomplicated diverticular disease.Digestive diseases and sciences · 2011Article
- Features and management of colonic diverticular disease.Current gastroenterology reports · 2010Review
- Diverticular disease: A therapeutic overview.World journal of gastrointestinal pharmacology and therapeutics · 2010Article
- The medical and nonoperative treatment of diverticulitis.Clinics in colon and rectal surgery · 2009Article
- [Modern therapy of diverticular disease].Der Internist · 2008Article
- Recent advances in the treatment of colonic diverticular disease and prevention of acute diverticulitis.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forty consecutive patients affected by recurrent attacks of symptomatic uncomplicated diverticular disease of the colon were evaluated to investigate the effectiveness of 2 different mesalazine therapeutic schedules in preventing recurrence of the disease. The patients were randomly enrolled and treated with mesalazine 1.6 g/d (group A) or mesalazine 1.6 g/d 10 days per month (group B). Thirty-four patients completed the study (85%): 3 (7.5%, 1 in group A and 2 in group B) were lost to follow-up, 2 (5%, both group B) were withdrawn from the study for protocol violation, and 1 (2.5%) for hospital admission for stroke (group A). Twenty-three patients (67.65%) were symptom free after 24 months of treatment (overall symptomatic score, 0): 14 of 18 in group A (per-protocol, 77.78%; intention to treat, 70% [95% confidence interval [CI], 61.5-91.8]), 9 of 16 in group B (per protocol, 56.25%; intention to treat, 45% [95% CI, 61.5-91.8]; P < 0.05). Four patients (10%) improved, but were not completely symptom free. Six patients (15%) showed recurrence of symptoms: 1 in group A (5.56%) and 5 in group B (31.25%; P < 0.005; overall symptomatic score, 68). Daily mesalazine supplying seems to be more effective than cyclic supplying in maintaining remission in recurrent symptomatic uncomplicated diverticular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.